Sino Biopharm 1177

[eauyong]

They have so much $2.3B cash, why they still need to raise cash?

Maybe the cash is gone with wind by now.

[eauyong]

Pharmas still down today.

Code // Name // Price // %

8143 // HUA XIA HEALTH // 0.103 // - 3.70%
2327 // JIWA BIO-PHARM // 0.53 // - 3.60%
2877 // SHINEWAY PHARM // 23.2 // - 2.90%
233 // MY MEDICARE // 0.86 // - 2.30%
587 // HUA HAN // 2.74 // - 2.10%
8158 // CHINA BIO-MED // 0.34 // - 1.40%
8049 // JILIN CHANGLONG // 0.81 // - 1.20%
8058 // LUOXIN PHARMA // 10.74 // - 1.10%
2005 // LIJUN INT'L // 2.85 // - 1.00%
1177 // SINO BIOPHARM // 3.13 // - 0.60%

[winston]

I think Pharmas will continue to be down until there's some clarity on what the government will be doing with regards to lowering drug prices.

[winston]

Not vested. PE 37

FINANCIAL HIGHLIGHTS

For the nine months ended 30 September, 2010, the Group recorded the following operational results:

– Turnover was approximately HK$3,011.44 million, an increase of approximately 21.7% over the same period last year;

– Profit attributable to the Group was approximately HK$320.14 million, approximately 16.8% higher than the same period last year;

– After the adjustment of the weighted average number of ordinary shares from the top-up placing of shares in January and June 2010, respectively, and from the share repurchase in April 2010, the basic earnings per share were approximately HK6.75 cents, approximately 11.6% higher than the corresponding period last year;

– Sales of new products accounted for approximately 22.7% of the Group’s total revenue; and

– Cash and bank balances as at 30 September, 2010 was approximately HK$2,580.64 million.

The Board of Directors (the “Directors”) of the Company declared a dividend payment of HK2 cents per share for the third quarter ended 30 September, 2010. Together with the quarterly dividend of HK2 cents per share paid in the first quarter and HK2 cents paid in the second quarter, the total dividend of the three quarters amounted to HK6 cents per share.

http://www.hkexnews.hk/listedco/listcon ... 116369.pdf

[winston]

not vested

Sino Biopharmaceutical [1177 HK] - Buy : Takeaways from HK Healthcare Corporate Day ( HKD2.22 / PT: HKD3.30 ) Gideon Lo

Stephen Tse, Executive Director form Sino Biopharmaceutical, shared his view on the company's growth outlook to our clients in the HK Healthcare Corporate Day.

He remains positive about the company's core earnings to sustain 25% in 2011-12, on the back of the strong growth in major drugs after the entry of the NDRL and the new product contribution.

He expects no major impact from the Fujian tender results due to
1) the growth in market share should compensate the lower drug price and 2) it is unlikely the Fujian tendering method to be followed by other provinces.

Maintain Buy.


Source: Nomura

[winston]

not vested

<Research Report>SINO BIOPHARM (01177.HK) maintained Neutral with TP lifted to HK$3 by GS
Aug 29, 2012

SINO BIOPHARM (01177.HK)'s second quarter and first-half turnover leaped 32% and 44.8% respectively to HK$1.94 billion and HK$3.92 billion, representing 26% and 53% of Goldman Sachs' full-year forecasts.

Goldman Sachs expects the 2012 sales and core earnings of SINO BIOPHARM to jump 30% and 20% respectively .

The broker also lifted its 2012-14 earnings per share forecasts for SINO BIOPHARM by 3%, 4% and 2% respectively.

SINO BIOPHARM was rated Neutral with target raised to HK$3 from HK$2.9.


Source: AAStocks Financial News

[winston]

not vested

<Research Report>SINO BIOPHARM (01177)'s TP lifted to HK$3.1 by BofA ML on expecting strong interim results
Jul 31, 2012

Bank of America Merrill Lynch said the first quarter results of SINO BIOPHARM (01177) were strong and management of the latter are confident the second quarter results will remain robust.

The broker raised its 2012 earnings forecast for SINO BIOPHARM by 6%.

SINO BIOPHARM was rated Buy with target lifted to HK$3.1 from HK$2.6.

The broker estimates the income and profit growth of SINO BIOPHARM in the first half of 2012 to soar 49% and 35% respectively.


Source: AAStocks Financial News

[winston]

<Research Report>SINO BIOPHARM (01177) to climb in next 60 days - MS
Jun 28, 2011

Morgan Stanley said, after meeting with the management of SINO BIOPHARM (01177), that it realized income growth of SINO BIOPHARM have not decelerated.

The broker expects SINO BIOPHARM's top products to continue to show strong growth.

It is highly likely for SINO BIOPHARM to give positive profit surprise, said the Morgan Stanley.

The broker also believes the mentioned stock is extremely likely to climb in the next 60 days.

Source: AAStocks Financial News

[winston]

not vested

SINO BIOPHARM (01177.HK) reiterated Buy with TP lifted to $3.5 by Deutsche

SINO BIOPHARM (01177.HK)'s income for the first three quarters reached $2.2 billion, in line with Deutsche Bank's estimate.

Management of SINO BIOPHARM lifted its 2012 growth rate target as well. As such, SINO BIOPHARM was reiterated Buy with target lifted to $3.5 from $3.3 by Deutsche Bank.

In the fourth quarter, the company would launch three new products and sales by year end are expected to touch $100 million, said SINO BIOPHARM's management as quoted by the broker.

Source: AAStocks Financial News

[winston]

not vested

SINO BIOPHARM (01177.HK) downgraded to Underperform - BofAML

CCTV programme 'Focus' reported that SINO BIOPHARM (01177.HK)'s subsidiary Jiangsu Chia-tai Tianqing Pharma paid physicians for trips, Bank of American Merrill Lynch said in a report, adding the news may trigger off systemic risks in the industry.

As a result, Bank of America Merrill Lynch downgrades SINO BIOPHARM (01177.HK) from Neutral to Underperform with target price reduced 27% to $4.2, and cut SINOPHARM (01099.HK), China's largest drug distributor, from Buy to Neutral with target price reduced 19% to $21, as SINOPHARM believably will be affected by industry downturn.

Source: AAStocks Financial News